Skip to content

EBITDA at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
-$132M-10.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.19M-438%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.09M+6.7%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

$108.5Mebit+
$688.0KDepreciation Depletion & Amortization
=-$107.86M

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s EBITDA?
IDEAYA Biosciences, Inc. (IDYA) reported EBITDA of -$107.86M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s EBITDA changed year-over-year?
IDEAYA Biosciences, Inc.'s EBITDA decreased by 28.7% year-over-year, from -$83.79M to -$107.86M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s EBITDA?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s EBITDA has grown at a 34.0% compound annual growth rate (CAGR), from -$48.54M to -$156.61M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.